Headquarters: Cambridge, Massachusetts, USA
Ticker: VYTR (NASDAQ)
Founded: 2013
Pipeline Focus: Gene therapy for neurological disorders
Overview
Mermaid diagram (expand to render)
Voyager Therapeutics is a clinical-stage biotechnology company focused on developing gene therapies for neurological diseases, with a particular emphasis on Parkinson's disease, Alzheimer's disease, and other neurodegenerative conditions. The company leverages its proprietary AAV vector platform and strategic partnerships to develop transformative therapies that address the underlying causes of neurological disorders["@voyager"].
Voyager's most advanced program, VY-AADC (also known as VYNAV-301), is a gene therapy for Parkinson's disease that aims to restore dopamine production by delivering the aromatic L-amino acid decarboxylase (AADC) gene directly to the striatum. This approach offers the potential for long-lasting symptom relief from a single treatment["@vyaadc"].
VY-AADC is Voyager's lead gene therapy program for Parkinson's disease. By delivering the AADC gene directly to the striatum, the therapy enables neurons that have lost dopamine-producing capacity to again synthesize dopamine, addressing the root cause of motor symptoms[@vyaadca].
Clinical Development:
Phase 1: Completed, demonstrating safety and proof-of-concept
These results support the potential for VY-AADC to provide meaningful, long-lasting benefits for patients with advanced Parkinson's disease[@longterm].
Research and Development Focus
Voyager's R&D strategy emphasizes:
Gene Replacement: Delivering functional copies of disease-causing genes
Gene Silencing: Using RNA interference to reduce toxic protein expression
Target Validation: Rigorous validation of therapeutic targets before clinical development
Combination Approaches: Exploring gene therapy combinations for enhanced efficacy
Leadership
CEO: Michael J. (former Biogen executive)
CSO: Dr. James M. (gene therapy pioneer)
CMO: Dr. Mark A. (former FDA reviewer)
Board: Includes scientific founders from Harvard and Massachusetts General Hospital